The ovaries are paired, almond-shaped female reproductive organs located in the pelvic cavity on each side of the uterus. They are responsible for producing ova, or eggs, and secreting the female sex hormones estrogen and progesterone. Ovarian cancer begins when abnormal cells in these organs or the surrounding fallopian tubes and peritoneum begin to multiply uncontrollably, forming a malignant tumor. Because the ovaries sit deep within the pelvic cavity, early tumors can grow significantly without causing obvious physical changes, which frequently delays initial detection.
Epithelial tumors spread primarily through direct shedding of malignant cells into the peritoneal cavity or via the lymphatic system.
Risk factors for ovarian cancer generally revolve around lifetime ovulation frequency and genetic predisposition. Women who experience an increased number of ovulatory cycles—such as those with early menarche, late menopause, or nulliparity—face a higher statistical risk. Conversely, factors that suppress ovulation, including prolonged oral contraceptive use, multiple pregnancies, and breastfeeding, offer a protective effect. Hereditary genetic mutations, particularly in the BRCA1 and BRCA2 genes, dramatically elevate both breast and ovarian cancer risks.
Ovarian cancer is historically known as the 'silent killer' because its early symptoms mimic common gastrointestinal complaints. Persistent abdominal bloating, pelvic or abdominal pain, difficulty eating, and feeling full quickly are key warning signs. Patients may also report urinary urgency or frequency due to tumor pressure on the bladder. When these vague symptoms persist daily for more than two weeks and are new for the patient, further clinical investigation is urgently required.
Diagnosing ovarian cancer requires a combination of clinical assessment and imaging. A transvaginal ultrasound is the primary imaging modality used to visualize ovarian masses and assess their internal characteristics. Blood tests checking for the tumor marker CA-125 are often ordered, though CA-125 can also be elevated in benign conditions like endometriosis or pelvic inflammatory disease. Definitive diagnosis requires surgical biopsy and histological examination of tissue samples.
Management of ovarian cancer typically involves primary debulking surgery followed by platinum-based chemotherapy. The goal of surgery is to remove as much visible tumor tissue as possible, often involving a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Chemotherapy agents like carboplatin and paclitaxel are administered postoperatively to eradicate remaining microscopic malignant cells. Targeted therapies, such as PARP inhibitors, are also utilized for patients with specific genetic mutation profiles.
Nurses play a critical role in managing postoperative recovery and monitoring for complications such as bowel obstruction, ascites, and deep vein thrombosis. Nursing interventions include pain management, assessing nutritional status, and monitoring surgical incision sites for infection. Education focuses on preparing the patient for chemotherapy side effects like fatigue, neuropathy, and hair loss. Emotional support is vital as patients navigate a diagnosis with high physical and psychological demands.